Dallas, Texas 09/24/2014 (ustradevoice) – Lipocine Inc (NASDAQ:LPCN) said its Phase 3 clinical study of LPCN 1021 was successful. It said the trial met the primary endpoint and managed to restore testosterone levels to the required range in 88% of the patients tested. Shares of the $69 million company gapped up more than 45% in the early afternoon Wednesday because of the positive study report. Lipocine Inc (NASDAQ:LPCN) intends to seek approval for the commercialization of the drug in the latter half of 2015. Lipocine Inc (NASDAQ:LPCN) is also working on another testosterone product. Low testosterone leads to symptoms such as loss of muscle mass, depression and loss of libido.

There was very little to keep investors clued in International Consolidated Companies Inc (OTCMKTS:INCC). They headed for the exit door and left the stock tumbling more than 4% in the early afternoon Wednesday. That happened even as the $67 million company recently announced its desire to be SEC reporting and compliant. Towards that end, International Consolidated Companies Inc (OTCMKTS:INCC) tapped ZBS Group, LLP, as its auditor. The certified public accountants and advisors would look into its financial statements, and once the auditing job is concluded, they will make SEC Form 10 filing. That development will put International Consolidated Companies Inc (OTCMKTS:INCC) on the path to becoming a fully reporting public company, which is important for its profile and shareholders.

Vapor Group Inc (OTCMKTS:VPOR)‘s financial health is improving, and the company cannot wait but make hay while the sun shines. At least in the sense that it wants to reduce its debt burden while it still has money to for that. Vapor Group Inc (OTCMKTS:VPOR) announced that it would pay down part of the more than $1 million convertible notes with interest rate of 8% that it issued to Hanover Holdings. The company reached out to Hanover for financing at a critical moment when it was facing burgeoning demand for its products, yet its capacity was stretched to the limits, making it impossible to meet the demand.